Literature DB >> 22447432

Infliximab for early endoscopic recurrence in patients with Crohn's disease.

Takayuki Yamamoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22447432     DOI： 10.1007/s10620-012-2121-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  5 in total

1.  Infliximab prevents Crohn's disease recurrence after ileal resection.

Authors:  Miguel Regueiro; Wolfgang Schraut; Leonard Baidoo; Kevin E Kip; Antonia R Sepulveda; Marilyn Pesci; Janet Harrison; Scott E Plevy
Journal:  Gastroenterology       Date:  2008-10-31       Impact factor: 22.682

2.  Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study.

Authors:  Takayuki Yamamoto; Satoru Umegae; Koichi Matsumoto
Journal:  Inflamm Bowel Dis       Date:  2009-10       Impact factor: 5.325

3.  Predictability of the postoperative course of Crohn's disease.

Authors:  P Rutgeerts; K Geboes; G Vantrappen; J Beyls; R Kerremans; M Hiele
Journal:  Gastroenterology       Date:  1990-10       Impact factor: 22.682

Review 4.  Factors affecting recurrence after surgery for Crohn's disease.

Authors:  Takayuki Yamamoto
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

5.  Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study.

Authors:  Dario Sorrentino; Giovanni Terrosu; Alberto Paviotti; Marco Geraci; Claudio Avellini; Giorgio Zoli; Walter Fries; Silvio Danese; Pietro Occhipinti; Tiziano Croatto; Dimitra Zarifi
Journal:  Dig Dis Sci       Date:  2012-01-18       Impact factor: 3.199
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.